MARK ASHBY: Open Payments
NPI 1063417616 · SEBRING, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$759 in 25 payments from 8 companies in 2025. Trend: 2023 $217 · 2024 $211 · 2025 $759
Food & beverage: $759
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $310 |
| Axsome Therapeutics, Inc. | 3 | $155 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Alkermes, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
Products named: CAPLYTA, Auvelity, REXULTI, FANAPT, COBENFY, ARISTADA, ABILIFY ASIMTUFII, TRINTELLIX.
Industry payments across FL — which companies pay providers there.
